ProKidney Corp
PROK1.890USD
+0.020+1.07%
交易中 （美東）報價延遲15分鐘
257.00M總市值
虧損本益比TTM
關於 ProKidney Corp 公司
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp簡介
公司代碼PROK
公司名稱ProKidney Corp
上市日期Jun 30, 2021
CEOCulleton (Bruce)
員工數量204
證券類型Ordinary Share
年結日Jun 30
公司地址2000 Frontis Plaza Blvd
城市WINSTON-SALEM
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編27103
電話13369997028
網址https://prokidney.com/
公司代碼PROK
上市日期Jun 30, 2021
CEOCulleton (Bruce)
ProKidney Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
其他
60.77%
持股股東
持股股東
佔比
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
其他
60.77%
股東類型
持股股東
佔比
Corporation
23.56%
Hedge Fund
11.04%
Investment Advisor
10.26%
Investment Advisor/Hedge Fund
6.12%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.04%
Family Office
0.02%
其他
45.52%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
178
41.09M
29.03%
-2.44M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Tolerantia LLC
22.62M
15.98%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.72%
--
--
Sep 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.58%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
6.41M
4.53%
+698.99K
+12.24%
Sep 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Oct 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Nov 30, 2025
Bleichroeder LP
2.00M
1.41%
--
--
Sep 30, 2025
Millennium Management LLC
1.96M
1.38%
+1.96M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.56M
1.1%
-3.75K
-0.24%
Sep 30, 2025
Culleton (Bruce)
1.54M
1.09%
+1.54M
--
Mar 17, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
查看更多
Schwab U.S. Small-Cap ETF
佔比0.01%
ALPS Medical Breakthroughs ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Avantis US Equity ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
